

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

ADOPTION OF NEW SHARE OPTION SCHEME

The board (the “**Board**”) of directors (the “**Directors**”) of the LifeTech Scientific Corporation (the “**Company**”) proposes to adopt a new share option scheme (the “**2019 Share Option Scheme**”) to operate concurrently with the existing share option scheme passed by the shareholders of the Company (the “**Shareholders**”) on 22 October 2011 (the “**Existing Scheme**”).

Pursuant to the Existing Scheme, the total number of ordinary shares of the Company (the “**Shares**”) which may be issued must not in aggregate exceed 400,000,000 representing 10% of the issued share capital of the Company (the “**Existing Scheme Limit**”) as at the applicable listing approval date. In view of the limited remaining scheme limit of the Existing Scheme and to optimise the scheme rules with streamlined administrative procedures, the Board proposes to Shareholders for the approval of the 2019 Share Option Scheme in order to facilitate the Company to provide rewards and motivation to employees and other eligible persons (the “**Eligible Participants**”) pursuant to the terms thereof for their contribution and continuing efforts to promote the interests of the Company for boosting the growth of the Company’s various businesses and the long-term interests of the Shareholders as a whole.

The 2019 Share Option Scheme will constitute a share option scheme under Chapter 17 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board will convene a general meeting for the purposes of, among other things, seeking the approval from the Shareholders for the adoption of the 2019 Share Option Scheme.

Application will be made to the Listing Committee of the Stock Exchange for the listing of and permission to deal in the new Shares which may be issued and allotted pursuant to the 2019 Share Option Scheme.

A circular containing, among other things, details of the 2019 Share Option Scheme will be despatched to the Shareholders in accordance with the requirements of the Listing Rules.

As at the date of this announcement, the 2019 Share Option Scheme remains subject to the approval of the Shareholders. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities.

By Order of the Board
LifeTech Scientific Corporation
XIE Yuehui
*Executive Director, Chairman and
Chief Executive Officer*

Hong Kong, 24 April 2019

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.